Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of LUCEMYRA in Adolescents with Opioid Withdrawal
NCT06711640Phase 1Withdrawn
- Sponsor
- US WorldMeds
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lofexidine in opioid withdrawal (2 arms), sponsored by US WorldMeds. Primary endpoint: Peak and trough plasma concentrations following daily LUCEMYRA doses. Planned start Jun 2025; status: withdrawn.
02
Drugs
lofexidine
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT06711640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711640.